When it comes to end-of-life decisions, it's often unclear whether doctors or patients should have the final say. The philosophical, legal, ethical and economic impacts of these challenging decisions about the type of care patients receive when they are near the end of their lives puts doctors in the hot seat, reports Medscape.
A shift in how antitrust officials examine the anticompetitive effects of mergers could add to the mounting challenges faced by the Aetna-Humana and Anthem-Cigna deals.
A new study from UCLA Health identifies factors that increase the likelihood of a patient being infected with antibiotic-resistant bacteria from tainted scopes.
A new coalition made up of national physician organizations and other groups, will press Congress to adopt comprehensive policies to combat the country's opioid epidemic.
Reports of behind-the-scenes bickering between Anthem and Cigna have reverberated in the stock market and raised further doubts about the likelihood the health insurers' merger will win approval.
A union-backed ballot initiative to equalize payments to hospitals in Massachusetts is raising significant concerns both within and outside the provider community. If passed by voters later this year, no hospital would be paid more than 20 percent above the statewide average for any medical procedure, according to The Boston Globe.
Doctors cite myriad reasons for not taking advantage of state prescription drug databases, even though health officials encourage the use of such tools more than ever in light of the country's opioid crisis.
Worries over the consequences of value-based payment methodologies in the Medicare Access and CHIP Reauthorization Act obscure significant improvements the rule makes over the status quo, writes Bob Doherty, senior vice president of Government Affairs and Public Policy at the American College of Physicians, in an article published in MedPage Today.
Tensions are rising between potential merger partners Anthem and Cigna, which could only make it more difficult for the two health insurance companies to win over federal regulators.
A pilot of a Google DeepMind kidney monitoring app with the National Health Service Royal Free Trust is moving forward despite reports it was halted now that it's fallen under regulatory scrutiny.